Similarly, in patients suffering from EGFR/ALK wild-type metastatic non-small-cell lung carcinoma, durvalumab and tremelimumab together with chemotherapy showed better OS and PFS benefit relative to chemotherapy in the phase III POSEIDON trial (NCT03164616) [42]. This evidence concerns the gene ALK and non-small cell lung carcinoma.